Posts

Showing posts with the label Pharma IP

API & IP Brief: FDA CGT Approvals Review, Sodium Thiosulfate Patent Ruling & Biopharma Updates

Image
API & IP Intelligence Brief: FDA Competitive Generic Therapy (CGT) Review & Purity Patent Rulings Target Keywords: Competitive Generic Therapy, CGT exclusivity, FDA ANDA approvals, Zydus Lifesciences, Amneal lanreotide, Hope Medical v Accord, sodium thiosulfate patent, API purity specifications, Paragraph IV litigation, Teva R&D Day . Six-Month FDA Competitive Generic Therapy (CGT) Review (Apr – Oct 2026) Between April 28 and October 19, 2026, the FDA approved 45 Abbreviated New Drug Applications (ANDAs) holding Competitive Generic Therapy (CGT) designations, up from 41 in the prior six-month period . However, only 12 approvals (27%) qualified for 180-day CGT market exclusivity, continuing a downward eligibility trend from 71% in 2019 to 26% so far in 2026 . Under Section 506H of the FD&C Act, CGT incentivises entry into off-patent or sole-source drugs facing inadequate generic competition . To unlock 180-day exclusivity, the first approved applicant must have ha...

API & IP Brief: Cipla’s Patent Landscape, Halozyme Keytruda Injunction & FDA Approvals

Image
Summary 5-minute read API & IP Intelligence Brief: Cipla’s Patent Landscape, Subcutaneous Keytruda Injunction, and Landmark FDA Approvals Target Keywords: Cipla patent filings, ready-to-use injectables, green propellants pMDI, Halozyme vs MSD, Keytruda SC injunction, bepirovirsen FDA approval, Climara Pro generic, API solid-state polymorphs, 505(b)(2) strategy . Executive Summary The latest edition of the API and IP Newsletter (November 9, 2026) provides an analytical view of formulation-led generic differentiation, critical biopharma patent enforcement, and key US regulatory milestones: Cipla Patent Filing Landscape (Oct 2024 – Oct 2026): Cipla published 28 patent families dominated by delivery improvements and API solid-state forms (86%), pivoting toward ready-to-use (RTU) hospital injectables and low-GWP propellant inhalers rather than primary discovery . Halozyme Secures European Injunction Against MSD’s Keytruda SC: The District Court of The Hague barred MSD from m...